Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Global incidence and mortality of severe fungal disease
Denning, D. W. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00692-8 · Cited by 1,640
Self-citationTackling the emerging threat of antifungal resistance to human health
Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E. M., Bowyer, P., Bromley, M., Brüggemann, R., Garber, G., Cornely, O. A., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00720-1 · Cited by 1,179
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
“After the inclusion of Indian data, the estimate of mucormycosis rose to 910,000 cases globally [23,24].”
BackgroundPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
“The burden of invasive fungal infections (IFIs) for patients and health care systems is difficult to measure [2, 12]; however, it is well recognized that IFIs are associated with high morbidity and mortality rates and elevated health care costs.”
BackgroundThreats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture
Fisher, M. C., Gurr, S. J., Cuomo, C. A., Blehert, D. S., Jin, H., Stukenbrock, E. H., Stajich, J. E., Kahmann, R., Boone, C., Denning, D. W., et al. (2020) · mBio · doi:10.1128/mbio.00449-20 · Cited by 536
Self-citationThe global incidence and diagnosis of fungal keratitis
Brown, L., Leck, A. K., Gichangi, M., Burton, M. J., & Denning, D. W. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30448-5 · Cited by 495
Self-citationAnti-Fungal Efficacy and Mechanisms of Flavonoids
Al Aboody, M. S., & Mickymaray, S. (2020) · Antibiotics · doi:10.3390/antibiotics9020045 · Cited by 472
“, skin, hair, nail infections (≈1,000,000,000), recurrent vulvovaginal candidiasis (≈134,000,000), rhinosinusitis (≈12,000,000), fungal asthma (≈10,000,000), allergic bronchopulmonary aspergillosis in bronchial asthma individuals (≈4,800,000), chronic pulmonary aspergillosis (3,000,000), oral candidiasis (≈2,000,000),…”
BackgroundCornely, O. A., Sprute, R., Bassetti, M., Chen, S. C.-A., Groll, A. H., Kurzai, O., Lass-Flörl, C., Ostrosky-Zeichner, L., Rautemaa-Richardson, R., Revathi, G., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00749-7 · Cited by 410
“22–24 Candidaemia is the most frequently diagnosed presentation of invasive candidiasis, 25 with most cases being health care-associated.”
Self-citationThe WHO fungal priority pathogens list as a game-changer
Fisher, M. C., & Denning, D. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00861-x · Cited by 399
Self-citationFungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications
Periferakis, A., Periferakis, K., Badarau, I. A., Petran, E. M., Popa, D. C., Caruntu, A., Costache, R. S., Scheau, C., Caruntu, C., & Costache, D. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315054 · Cited by 362
“Finally, Cryptococcus neoformans is one of the deadliest fungal pathogens [334] and, according to a recent survey kills thousands of infected patients each year [335].”
BackgroundVulvovaginal Candidiasis: A Current Understanding and Burning Questions
Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020) · Journal of Fungi · doi:10.3390/jof6010027 · Cited by 357
“009% 7,800,000,000 702,000 [8] Oropharyngeal 15,337,200 HIV/AIDS 2 72.”
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
Fungal diseases as neglected pathogens: A wake-up call to public health officials
Rodrigues, M. L., & Nosanchuk, J. D. (2020) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0007964 · Cited by 342
“Globally, the latest estimates suggest an annual occurrence of approximately 3 million cases of chronic pulmonary aspergillosis, over 200,000 cases of cryptococcal meningitis, 700,000 cases of invasive candidiasis, 500,000 cases of Pneumocystis jirovecii pneumonia, 250,000 cases of invasive aspergillosis, 100,000 case…”
BackgroundInfluentialThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
“Globally, there may be as many as 250,000 cases of invasive aspergillosis and 3 million cases of chronic pulmonary aspergillosis each year 85 .”
BackgroundAntifungal Agents in Agriculture: Friends and Foes of Public Health
Brauer, V. S., Rezende, C. P., Pessoni, A. M., De Paula, R. G., Rangappa, K. S., Nayaka, S. C., Gupta, V. K., & Almeida, F. (2019) · Biomolecules · doi:10.3390/biom9100521 · Cited by 305
“Recent global estimates have revealed approximately 3,000,000, 250,000, 700,000, and 223,100 cases of chronic pulmonary aspergillosis, invasive aspergillosis, invasive candidiasis, and cryptococcal meningitis among AIDS patients [13].”
BackgroundNeuroinfections caused by fungi
Góralska, K., Blaszkowska, J., & Dzikowiec, M. (2018) · Infection · doi:10.1007/s15010-018-1152-2 · Cited by 295
“The incidence of fungal infections is increasing every year, with greater numbers of infections noted among patients belonging to high-risk groups such as HIV-infected persons and AIDS patients, transplant recipients, and immunosuppressed patients treated with chemotherapeutics or corticosteroids, as well as those suf…”
BackgroundCandida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
“Biofilms are also associated with recurrent candidaemia, which affects more than 400 000 people per year and has an alarming mortality rate of approximately 50% (Tumbarello et al. 2012; Bongomin et al. 2017; Li et al. 2018).”
BackgroundEchinocandins – structure, mechanism of action and use in antifungal therapy
Szymański, M., Chmielewska, S., Czyżewska, U., Malinowska, M., & Tylicki, A. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2050224 · Cited by 270
“The synthesis of b-(1,3)-D-glucan is catalysed by UDP-glucose (1,3)-D-glucan-b-(3)-D-glucosyltransferase, referred to as b-(1,3)-Dglucan synthase (EC 2.”
BackgroundInfluentialAntifungal Peptides as Therapeutic Agents
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00105 · Cited by 264
“It is estimated that fungal diseases affect more than one billion people globally, of whom 150 million suffer from severe infections (Bongomin et al., 2017).”
BackgroundHoušť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
“The recent annual incidence of invasive aspergillosis, candidiasis, and mucormycosis is over 300,000, 750,000, and 10,000 cases, respectively [3].”
BackgroundWitchley, J. N., Penumetcha, P., Abon, N. V., Woolford, C. A., Mitchell, A. P., & Noble, S. M. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.02.008 · Cited by 240
“As the most common fungal pathogen of humans, Candida albicans causes hundreds of millions of symptomatic infections each year (Bongomin et al., 2017; Brown et al., 2012; Pfaller and Diekema, 2007).”
BackgroundEvolution of the human pathogenic lifestyle in fungi
Rokas, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01112-0 · Cited by 232
Antifungal Drug Resistance: An Emergent Health Threat
Vitiello, A., Ferrara, F., Boccellino, M., Ponzo, A., Cimmino, C., Comberiati, E., Zovi, A., Clemente, S., & Sabbatucci, M. (2023) · Biomedicines · doi:10.3390/biomedicines11041063 · Cited by 228
“Serum concentrations of voriconazole can have considerable interpatient variability, with demonstrated higher hepatotoxicity rate in Asian vs. non-Asian populations [26].”
BackgroundInfluentialPrevalence and Healthcare Burden of Fungal Infections in the United States, 2018
Rayens, E., & Norris, K. A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab593 · Cited by 228
“5 million deaths globally per year, primarily in those with some compromised immune function [1].”
BackgroundThe importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Kean, R., Delaney, C., Sherry, L., Borman, A., Johnson, E. M., Richardson, M. D., Rautemaa-Richardson, R., Williams, C., & Ramage, G. (2018) · mSphere · doi:10.1128/msphere.00334-18 · Cited by 220
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Faustino, C., & Pinheiro, L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010029 · Cited by 203
“Nevertheless, fungal pathogens remain mostly neglected by public health authorities and research funding bodies, despite their strong impact on human health and crop production that results in high social and economic burdens [1,6].”
BackgroundEssential Oils of Lamiaceae Family Plants as Antifungals
Karpiński, T. M. (2020) · Biomolecules · doi:10.3390/biom10010103 · Cited by 202
“6 million, which is >3-fold more than malaria [3].”
BackgroundMechanistic Understanding of Candida albicans Biofilm Formation and Approaches for Its Inhibition
Atriwal, T., Azeem, K., Husain, F. M., Hussain, A., Khan, M. N., Alajmi, M. F., & Abid, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.638609 · Cited by 201
The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation
Casalini, G., Giacomelli, A., & Antinori, S. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00042-9 · Cited by 197
Mechanisms of Antifungal Properties of Metal Nanoparticles
Slavin, Y. N., & Bach, H. (2022) · Nanomaterials · doi:10.3390/nano12244470 · Cited by 198
“6 million deaths yearly, a number over 3-fold higher than malaria estimates and comparable to tuberculosis [6].”
BackgroundMolecular diagnostics in medical mycology
Wickes, B. L., & Wiederhold, N. P. (2018) · Nature Communications · doi:10.1038/s41467-018-07556-5 · Cited by 188
Invasive candidiasis: current clinical challenges and unmet needs in adult populations
Soriano, A., Honore, P. M., Puerta-Alcalde, P., Garcia-Vidal, C., Pagotto, A., Gonçalves-Bradley, D. C., & Verweij, P. E. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad139 · Cited by 190
Invasive fungal disease in humans: are we aware of the real impact?
Firacative, C. (2020) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760200430 · Cited by 184
“Disseminated histoplasmosis Histoplasma capsulatum ~ 100,000(6) 10 -60(42)”
BackgroundInfluentialThe fungal cell wall as a target for the development of new antifungal therapies
Cortés, J. C. G., Curto, M.-Á., Carvalho, V. S. D., Pérez, P., & Ribas, J. C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.02.008 · Cited by 170
Candida albicans and Candida glabrata : global priority pathogens
Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-23 · Cited by 180
Burks, C., Darby, A., Gómez Londoño, L., Momany, M., & Brewer, M. T. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009711 · Cited by 159
“CPA was estimated to affect 3 million people annually in 2017, but it is also documented that the disease is underrecognized so incidence cannot be accurately estimated [4,5].”
BackgroundInfluentialGeddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
“Specifically, the growing prevalence of fungal infections is directly associated with ever-increasing rates of medical vulnerabilities, including (1) immunosuppression, which is becoming more common as a result of HIV/AIDS,10,11 hematologic cancers and cancer chemotherapeutics,12,13 the use of immunosuppressive agents…”
BackgroundVerweij, P. E., Lucas, J. A., Arendrup, M. C., Bowyer, P., Brinkmann, A. J. F., Denning, D. W., Dyer, P. S., Fisher, M. C., Geenen, P. L., Gisi, U., et al. (2020) · Fungal Biology Reviews · doi:10.1016/j.fbr.2020.10.003 · Cited by 152
Self-citationDrug Delivery Strategies and Biomedical Significance of Hydrogels: Translational Considerations
Raina, N., Pahwa, R., Bhattacharya, J., Paul, A. K., Nissapatorn, V., de Lourdes Pereira, M., Oliveira, S. M. R., Dolma, K. G., Rahmatullah, M., Wilairatana, P., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030574 · Cited by 158
Mycotic Keratitis—A Global Threat from the Filamentous Fungi
Hoffman, J. J. S. L., Burton, M. J., & Leck, A. (2021) · Journal of Fungi · doi:10.3390/jof7040273 · Cited by 180
“The burden of FK is greatest in tropical and subtropical countries, accounting for between 20 and 60% of MK cases presenting in tropical regions [6], likely a result of climate (higher temperatures and relative humidity) and frequent agriculture-related ocular trauma [7].”
BackgroundHoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00872-6 · Cited by 152
Pathogenesis of Respiratory Viral and Fungal Coinfections
Salazar, F., Bignell, E., Brown, G. D., Cook, P. C., & Warris, A. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00094-21 · Cited by 178
Apigenin: A Bioflavonoid with a Promising Role in Disease Prevention and Treatment
Allemailem, K. S., Almatroudi, A., Alharbi, H. O., Alsuhaymi, N., Alsugoor, M. H., Aldakheel, F. M., Khan, A. A., & Rahmani, A. H. (2024) · Biomedicines · doi:10.3390/biomedicines12061353 · Cited by 184
“Antifungal activity Fungi can lead to a range of illnesses in humans, from allergic reactions to superficial as well as potentially life-threatening invasive fungal diseases, affecting over one billion people globally [178,179].”
BackgroundElhamouly, N. A., Hewedy, O. A., Zaitoon, A., Miraples, A., Elshorbagy, O. T., Hussien, S. M., El-Tahan, A. M., & Peng, D. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.1044896 · Cited by 174
“Finding new targets for antifungal therapy is crucial since pathogenic fungi routinely display dangerously high levels of resistance to conventional antifungal medications in clinical settings, especially those targeting the electron transport chain (Bongomin et al., 2017).”
BackgroundWaghule, T., Rapalli, V. K., Singhvi, G., Manchanda, P., Hans, N., Dubey, S. K., Hasnain, M. S., & Nayak, A. K. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.026 · Cited by 153
Mechanism of Candida pathogenesis: Revisiting the vital drivers
Mba, I. E., & Nweze, E. I. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03912-w · Cited by 143
Jenks, J. D., & Hoenigl, M. (2018) · Journal of Fungi · doi:10.3390/jof4030098 · Cited by 174
“The 2017 global estimates indicated that more than 3,000,000 cases of chronic pulmonary aspergillosis (CPA), and ≈250,000 cases of invasive aspergillosis (IA) occur annually [6].”
BackgroundA comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Howard, K. C., Dennis, E. K., Watt, D. S., & Garneau-Tsodikova, S. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00556k · Cited by 140
Synthesis of Chitosan-Based Gold Nanoparticles: Antimicrobial and Wound-Healing Activities
Hashem, A. H., Shehabeldine, A. M., Ali, O. M., & Salem, S. S. (2022) · Polymers · doi:10.3390/polym14112293 · Cited by 149
From Jekyll to Hyde: The Yeast–Hyphal Transition of Candida albicans
Chow, E. W. L., Pang, L. M., & Wang, Y. (2021) · Pathogens · doi:10.3390/pathogens10070859 · Cited by 177
Vaccines for human fungal diseases: close but still a long way to go
Oliveira, L. V. N., Wang, R., Specht, C. A., & Levitz, S. M. (2021) · npj Vaccines · doi:10.1038/s41541-021-00294-8 · Cited by 135
Combatting the evolution of antifungal resistance in Cryptococcus neoformans
Bermas, A., & Geddes‐McAlister, J. (2020) · Molecular Microbiology · doi:10.1111/mmi.14565 · Cited by 155
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance
Ellsworth, M., & Ostrosky-Zeichner, L. L. (2020) · Journal of Fungi · doi:10.3390/jof6040324 · Cited by 149
“The high mortality rate in combination with limited treatment options leads to over 1.5 million deaths / year worldwide [2].”
InfluentialBhunjun, C. S., Phillips, A. J. L., Jayawardena, R. S., Promputtha, I., & Hyde, K. D. (2021) · Pathogens · doi:10.3390/pathogens10091096 · Cited by 186
“Pathogenic fungi can also cause diseases in humans ranging from superficial infections to invasive infection that can lead to mortality [16].”
BackgroundHealthy Vaginal Microbiota and Influence of Probiotics Across the Female Life Span
Lehtoranta, L., Ala‐Jaakkola, R., Laitila, A., & Maukonen, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.819958 · Cited by 166
Recent trends in molecular diagnostics of yeast infections: from PCR to NGS
Consortium OPATHY, Arastehfar, A., Boekhout, T., Butler, G., De Cesare, G. B., Dolk, E., Gabaldón, T., Hafez, A., Hube, B., Hagen, F., et al. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz015 · Cited by 131
Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention
Holmes, C. L., Albin, O. R., Mobley, H. L. T., & Bachman, M. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01105-2 · Cited by 183
“Candida species, the principal fungal bloodstream pathogens, are associated with high infection rates in immunocompromised individuals 45,46 .”
Antimicrobial Importance of Medicinal Plants in Nigeria
Ugboko, H. U., Nwinyi, O. C., Oranusi, S. U., Fatoki, T. H., & Omonhinmin, C. A. (2020) · The Scientific World JOURNAL · doi:10.1155/2020/7059323 · Cited by 182
García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143
“5 million people die from fungal diseases each year [1,2].”
BackgroundMechanisms of fungal dissemination
Strickland, A. B., & Shi, M. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03736-z · Cited by 127
Adaptogenic effects of Panax ginseng on modulation of immune functions
Ratan, Z. A., Youn, S.-H., Kwak, Y.-S., Han, C.-K., Haidere, M. F., Kim, J. K., Min, H., Jung, Y.-J., Hosseinzadeh, H., Hyun, S. H., et al. (2020) · Journal of Ginseng Research · doi:10.1016/j.jgr.2020.09.004 · Cited by 149
“Skin, nail, and hair are usually infected with fungi, over 150 million people around the world experiencing serious cases, and this infection can be fatal [72].”
BackgroundBrandão, P., Marques, C. S., Burke, A. J., & Piñeiro, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113102 · Cited by 138
Fungal infections diagnosis – Past, present and future
Mendonça, A., Santos, H., Franco‐Duarte, R., & Sampaio, P. (2021) · Research in Microbiology · doi:10.1016/j.resmic.2021.103915 · Cited by 144
The Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
Zagórska-Dziok, M., & Sobczak, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050396 · Cited by 132
Branco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 165
Membrane-Interacting Antifungal Peptides
Struyfs, C., Cammue, B. P. A., & Thevissen, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.649875 · Cited by 140
Peng, K., Vora, L. K., Tekko, I. A., Permana, A. D., Domínguez-Robles, J., Ramadon, D., Chambers, P., McCarthy, H. O., Larrañeta, E., & Donnelly, R. F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.001 · Cited by 122
Pathophysiological aspects of Aspergillus colonization in disease
Gago, S., Denning, D. W., & Bowyer, P. (2018) · Medical Mycology · doi:10.1093/mmy/myy076 · Cited by 135
Self-citationInvasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches
Jenks, J. D., Nam, H. H., & Hoenigl, M. (2021) · Mycoses · doi:10.1111/myc.13274 · Cited by 140
Fungal Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management
Thompson, G. R., Jenks, J. D., Baddley, J. W., Lewis, J. S., Egger, M., Schwartz, I. S., Boyer, J., Patterson, T. F., Chen, S. C. ‐., Pappas, P. G., et al. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-23 · Cited by 167
“In 2017, an estimated 15 million cases of pulmonary and other forms of IFD occurred worldwide (2).”
BackgroundThe Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era
Mazi, P. B., Sahrmann, J. M., Olsen, M. A. A., Coler-Reilly, A. L. G., Rauseo, A. M., Pullen, M. F., Zuniga-Moya, J. C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac882 · Cited by 131
Epidemiology and Diagnostic Perspectives of Dermatophytoses
Petrucelli, M. F., de Abreu, M. H., Cantelli, B. A. M., Segura, G. G., Nishimura, F. G., Bitencourt, T. A., Marins, M., & Fachin, A. L. (2020) · Journal of Fungi · doi:10.3390/jof6040310 · Cited by 164
“Some conditions are necessary for the establishment of this infection in the patient, including an immunosuppressive state, obesity, diabetes, and advanced age, in addition to other health problems [35].”
BackgroundInvasive candidiasis species distribution and trends, United States, 2009-2017
Ricotta, E. E., Lai, Y. L., Babiker, A., Strich, J. R., Kadri, S. S., Lionakis, M. S., Prevots, D. R., & Adjemian, J. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa502 · Cited by 114
“These methodological differences hamper efforts to obtain accurate estimates of the burden of IC in the United States and globally, and may result in an underestimation of the true number of cases [5, 21].”
BackgroundJuvvadi, P. R., Fox, D., Bobay, B. G., Hoy, M. J., Gobeil, S. M. C., Venters, R. A., Chang, Z., Lin, J. J., Averette, A. F., Cole, D. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12199-1 · Cited by 116
El‐Saadony, M. T., Saad, A. M., Mohammed, D. M., Alkafaas, S. S., Ghosh, S. B., Negm, S. H., Salem, H. M., Fahmy, M. A., Mosa, W. F. A., Ibrahim, E. H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603018 · Cited by 183
Ahmed, M. M., Fatima, F., Anwer, M. K., Ibnouf, E. O., Kalam, M. A., Alshamsan, A., Aldawsari, M. F., Alalaiwe, A. S., & Ansari, M. J. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.04.010 · Cited by 142
“The progression of fungal infections can be rapid and serious due to compromising immune function (Bongomin et al., 2017).”
BackgroundThe global burden of chromoblastomycosis
Santos, D. W. D. C. L., de Azevedo, C. D. M. P. E. S., Vicente, V. A., Queiroz‐Telles, F., Rodrigues, A. M., de Hoog, S., Denning, D. W., & Colombo, A. L. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009611 · Cited by 114
“Review papers were selected only to find references to original papers to avoid case duplication [2,15].”
BackgroundSelf-citationSerology anno 2021—fungal infections: from invasive to chronic
Lass‐Flörl, C., Samardzic, E., & Knoll, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.02.005 · Cited by 123
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“1 to 21 cases per 100,000 population) [4], with an associated crude mortality rate in excess of 40% and an associated expenditure of ~$46,000 per case [7].”
Backgroundvan Rhijn, N., & Bromley, M. (2021) · Journal of Fungi · doi:10.3390/jof7050367 · Cited by 132
“The rates of infection in India and Pakistan are 100 times higher than this at c. 14 cases per 100,000 individuals, pushing the annual global incidence up to 300,000.”
BackgroundInfluentialUrban, K., Chu, S., Scheufele, C. J., Giesey, R. L., Mehrmal, S., Uppal, P., & Delost, G. R. (2020) · JAAD International · doi:10.1016/j.jdin.2020.10.003 · Cited by 132
“INTRODUCTION Fungal skin diseases are extremely common, with nearly a billion people worldwide estimated to suffer from dermatomycoses or fungal infections of the skin, hair, and nails.(1) The prevalence and incidence of dermatomycoses vary with socioeconomic and geographic differences.”
BackgroundPathogenicity and virulence of Aspergillus fumigatus
Earle, K., Valero, C., Conn, D. P., Vere, G., Cook, P. C., Bromley, M., Bowyer, P., & Gago, S. (2023) · Virulence · doi:10.1080/21505594.2023.2172264 · Cited by 132
“Yet, despite fungal respiratory infections causing as many deaths as Influenza or Tuberculosis annually, they remain overlooked [2–4].”
BackgroundResultInfluentialSelf-citationC5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection
Desai, J. V., Kumar, D., Freiwald, T., Chauss, D., Johnson, M. D., Abers, M. S., Steinbrink, J. M., Perfect, J. R., Alexander, B. D., Matzaraki, V., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.031 · Cited by 109
Regulation of Candida albicans Hyphal Morphogenesis by Endogenous Signals
Kornitzer, D. (2019) · Journal of Fungi · doi:10.3390/jof5010021 · Cited by 106
“Candidiasis is currently responsible for an estimated 700,000 annual deaths worldwide [15].”
BackgroundThe Mycobiome in Health and Disease: Emerging Concepts, Methodologies and Challenges
Tiew, P. Y., Aogáin, M. M., Ali, N. A. B. M., Thng, K. X., Goh, K., Lau, K. J. X., & Chotirmall, S. H. (2020) · Mycopathologia · doi:10.1007/s11046-019-00413-z · Cited by 139
Ksiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
“Candida species are among the main causes of hospital-acquired fungal infections.(1) C.”
Bretagne, S., Sitbon, K., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Letscher‐Bru, V., Cassaing, S., Millon, L., Morio, F., Gangneux, J., Hasseine, L., et al. (2022) · mBio · doi:10.1128/mbio.00920-22 · Cited by 127
“available based on publications from reference laboratories (1).”
BackgroundAdvancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 142
Akbar, S., Zou, Q., Raza, A., & Alarfaj, F. K. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102860 · Cited by 119
Mechanisms of Pathogenic Candida Species to Evade the Host Complement Attack
Singh, D. K., Tóth, R., & Gácser, A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00094 · Cited by 135
“A recent review summarized data from 39 papers containing reports from across the globe and estimated a total of 159,253 candidemia episodes by August 2017, including a high prevalence in Pakistan followed by Brazil and Russia with the lowest incidence in Jamaica, Austria, and Portugal (Bongomin et al., 2017).”
BackgroundElbasuney, S., El-Sayyad, G. S., Tantawy, H., & Hashem, A. H. (2021) · RSC Advances · doi:10.1039/d1ra04542c · Cited by 105
RetractedMcCreary, E. K., Davis, M. R., Narayanan, N., Andes, D. R., Cattaneo, D., Christian, R., Lewis, R. E., Watt, K., Wiederhold, N. P., & Johnson, M. D. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2850 · Cited by 123
New Antifungal Agents with Azole Moieties
Teixeira, M. M., Carvalho, D. T., Sousa, E., & Pinto, E. (2022) · Pharmaceuticals · doi:10.3390/ph15111427 · Cited by 140
“7 million deaths annually (according to a 2017 study) [1,2].”
BackgroundAntifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 133
“The large majority of situations are easily treated but, as previously described, there is growing concern regarding the alteration in the epidemiology and the emergence of resistance to antifungal drugs [16,35].”
BackgroundNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
An Overview on Candida auris in Healthcare Settings
Cristina, M. L., Spagnolo, A. M., Sartini, M., Carbone, A., Oliva, M., Schinca, E., Boni, S., & Pontali, E. (2023) · Journal of Fungi · doi:10.3390/jof9090913 · Cited by 124
“C. auris and other fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [44].”
BackgroundInfluentialA Decade of Antifungal Leads from Natural Products: 2010–2019
Aldholmi, M., Marchand, P., Ourliac‐Garnier, I., Pape, P. L., & Ganesan, A. (2019) · Pharmaceuticals · doi:10.3390/ph12040182 · Cited by 113
“5 million 33 deaths each year, is equivalent to that caused by tuberculosis and more than triple that of malaria [1].”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.